PMID- 14743961
OWN - NLM
STAT- MEDLINE
DCOM- 20040831
LR  - 20190823
IS  - 0036-5513 (Print)
IS  - 0036-5513 (Linking)
VI  - 63
IP  - 7-8
DP  - 2003
TI  - Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe 
      hypercholesterolaemia.
PG  - 513-9
AB  - OBJECTIVES: To investigate whether plasma concentrations of monocyte 
      chemoattractant protein-1 (MCP-1) and the gene expression of its receptor on the 
      monocyte cell surface CCR-2 were elevated above normal in subjects with 
      asymptomatic, isolated hypercholesterolaemia and if statin treatment could 
      influence this cytokine. METHODS: The investigation was designed as a cross 
      sectional study followed by a single, blind, treatment study of patients 
      receiving pravastatin 80 mg/day for 8 weeks. The study included 23 patients with 
      severe hypercholesterolaemia (LDL>5.2 mmol/L) and 39 normocholesterolaemic 
      controls. Blood samples were obtained from patients and controls at baseline and 
      from patients at end of the study and analysed for lipoproteins and inflammatory 
      mediators: MCP-1. high-sensitivity C-reactive protein (HS-CRP). Isolated 
      peripheral mononuclear cells were analysed for CCR-2 gene expression. RESULTS: 
      Mean plasma LDL-C was significantly higher in patients than in controls. No 
      difference in plasma MCP-1 levels or CCR-2 gene expression was seen between the 
      groups at baseline, nor were there any differences in plasma concentrations of 
      CRP. After treatment with pravastatin, LDL-C decreased by 31%. Treatment did not 
      significantly affect the levels of MCP-1 or CCR-2 gene expression, nor was CRP 
      affected by treatment with pravastatin. CONCLUSIONS: Our study does not support 
      the view that MCP-1 plasma levels and CCR-2 gene expression in circulating 
      monocytes are directly responsible for the monocyte recruitment into the arterial 
      intima in patients with severe asymptomatic hypercholesterolaemia. In addition, 
      the inflammatory response of a high concentration of LDL-C in isolated 
      asymptomatic hypercholesterolaemia is minute.
FAU - Blomqvist, H M
AU  - Blomqvist HM
AD  - Division of Internal Medicine, Department of Medicine and Care, Clinical Research 
      Center, Faculty of Health Sciences, Linkoping, Sweden. 
      henrik.blomqvist@imv.liu.se
FAU - Olsson, A G
AU  - Olsson AG
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Apolipoproteins B)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Receptors, CCR2)
RN  - 0 (Receptors, Chemokine)
RN  - 0 (Triglycerides)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticholesteremic Agents/pharmacology
MH  - Apolipoprotein A-I/blood/drug effects
MH  - Apolipoproteins B/blood/drug effects
MH  - C-Reactive Protein/analysis
MH  - Chemokine CCL2/*blood
MH  - Cholesterol/blood
MH  - Cholesterol, HDL/blood/drug effects
MH  - Cholesterol, LDL/blood/drug effects
MH  - Cross-Sectional Studies
MH  - Female
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Hypercholesterolemia/blood/*drug therapy/metabolism
MH  - Male
MH  - Middle Aged
MH  - Pravastatin/*pharmacology
MH  - Receptors, CCR2
MH  - Receptors, Chemokine/*genetics
MH  - Single-Blind Method
MH  - Triglycerides/blood
EDAT- 2004/01/28 05:00
MHDA- 2004/09/01 05:00
CRDT- 2004/01/28 05:00
PHST- 2004/01/28 05:00 [pubmed]
PHST- 2004/09/01 05:00 [medline]
PHST- 2004/01/28 05:00 [entrez]
AID - 10.1080/00365510310003274 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2003;63(7-8):513-9. doi: 10.1080/00365510310003274.